at Zacks.com (Oct 30, 2014)
Synergy Pharma (SGYP -3.7%) slips despite presenting positive safety and efficacy results from trials of plecanatide, its drug candidate for patients with chronic idiopathic constipation at an industry conference earlier in Orlando, Florida. The data showed the best improvement in symptoms were observed in patients receiving 3-milligram doses of plecanatide.
From other sites
at MarketWatch.com (Jan 2, 2013)
at Fox Business (Aug 30, 2012)
at MarketWatch.com (May 4, 2012)